FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor-α, ameliorates endotoxin-induced shock
- 30 May 1997
- journal article
- Published by Elsevier BV in European Journal of Pharmacology
- Vol. 327 (2-3), 169-174
- https://doi.org/10.1016/s0014-2999(97)89657-4
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Nitric oxide and septic shockJAMA, 1996
- Combined Inhibition of Interleukin-1 and Tumor Necrosis Factor in Rodent Endotoxemia: Improved Survival and Organ FunctionThe Journal of Infectious Diseases, 1995
- Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthaseCell, 1995
- Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study GroupJAMA, 1994
- Cytokines in context.The Journal of cell biology, 1991
- Interleukin-1 receptor antagonist reduces mortality from endotoxin shockNature, 1990
- Circulating Interleukin-1 and Tumor Necrosis Factor in Septic Shock and Experimental Endotoxin FeverThe Journal of Infectious Diseases, 1990
- Tumor Necrosis Factor and Interleuktn-1 in the Serum of Children with Severe Infectious PurpuraNew England Journal of Medicine, 1988
- Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.JCI Insight, 1988
- Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of EndotoxinScience, 1985